查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081581

非處方藥市場：2026-2032 年全球市場以藥物類型、劑型、通路、年齡層和最終用戶預測。

Over The Counter Drugs Market by Drug Type, Product Form, Distribution Channel, Age Group, End-user - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非處方藥市場規模將成長至 1,039.6 億美元，複合年成長率為 9.03%。

主要市場統計數據
基準年 2025 567.5億美元
預計年份：2026年 615億美元
預測年份 2032 1039.6億美元
複合年成長率 (%) 9.03%

非處方藥市場是全球自我護理的重要支柱，消費者無需處方即可使用非處方藥來應對疼痛、發燒、過敏、咳嗽和感冒症狀、消化器官系統問題、皮膚問題以及輕微感染疾病等常見疾病，只需按照處方箋使用即可。包括美國食品藥物管理局（FDA）、歐洲監管機構以及亞太地區衛生署在內的監管機構，持續透過安全標準、標籤規範、劑量控制和藥物安全監測等措施來監管成藥的供應。

人口老化、健康意識增強、自付醫療費用上漲以及藥局、量販店和電商通路的擴張是推動市場需求的主要因素。此外，處方藥向非處方藥（OTC）的轉變、標籤的改進、值得信賴的成藥品牌以及消費者所需的便捷一線治療方案的普及，也促進了該品類的發展。對於行業供應商而言，成長的關鍵在於平衡藥品可及性與實證安全性、透明的療效標籤、可靠的供應以及負責任的數位互動。

成藥產業的變革

成藥市場正從產品主導零售模式轉向以消費者為中心的自我護理生態系統。儘管藥局仍然是值得信賴的網路基地台，但電子商務、遠端醫療行動醫療和全通路訂單履行正在改變消費者發現、比較和購買成藥的方式。這種轉變凸顯了受監管的數位內容、清晰的使用指南以及基於症狀的搜尋查詢的搜尋性日益成長的重要性。

人工智慧對成藥的累積影響

人工智慧 (AI) 正在為非處方成藥)的整個價值鏈帶來累積優勢。製造商和零售商正在利用 AI 進行需求預測、庫存規劃、搜尋最佳化、消費者情緒分析、客服中心支援以及用於藥物安全監測的訊號檢測。這些功能在咳嗽、感冒、流感和過敏產品等季節性產品類別中尤其重要，因為這些產品的需求會根據當地和公共衛生狀況迅速變化。

關於非處方成藥) 的關鍵區域見解

亞太地區是非成藥市場最具活力的地區之一，這得益於其龐大的人口基數、不斷壯大的中產階級、都市區藥房的現代化以及線上健康零售的快速發展。儘管中國、印度、日本、韓國、澳洲和東協等市場的監管模式各不相同，但它們都受到消費者健康意識不斷增強、部分經濟體人口老齡化以及消費者對便捷的自我治療（例如止痛藥、腸胃藥、抗過敏藥、皮膚科產品以及感冒、咳嗽和流感藥物）日益成長的需求等因素的共同驅動。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

由於都市化加快、零售藥局網路擴張以及行動優先消費者的興起，東協市場的重要性日益凸顯，這改善了主要城市和新興區域地區非處方藥的可及性。然而，監管協調進程仍然緩慢，因此，參與策略必須考慮到各國的具體標籤、註冊、進口要求、當地語言標準以及衛生當局的期望。

來自主要國家關於成藥的見解

美國憑藉其大規模的零售網路、FDA專論標準、激烈的自有品牌競爭、直接面對消費者的教育以及消費者持續成長的從處方藥轉向非處方藥的需求，引領著全球非處方藥創新。加拿大則強調雙語標示、藥局信任以及為注重安全的消費者提供便利。墨西哥和巴西憑藉較高的藥房使用率、不斷擴展的都市區零售網路以及對價格合理的緩解症狀藥物的需求，在拉丁美洲市場佔據重要地位。

成藥行業領導者提供的實用建議

業內供應商應優先拓展其在需求量大的非處方藥（OTC）類別中基於循證醫學的產品系列，例如鎮痛藥、抗過敏藥、胃腸道舒緩藥、皮膚科用藥以及咳嗽、感冒和流感藥物。評估從處方藥轉向非處方藥的機會時，應考慮以下因素：安全性歷史、消費者對標籤的理解、誤用風險、劑量清晰度、上市後監測準備情況以及藥劑師支援需求。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，符合市場情報的最佳實踐。其資訊來源包括：美國食品藥物管理局（FDA）、歐洲衛生當局和各國衛生署等監管機構的指導意見；世界衛生組織（WHO）和經濟合作暨發展組織（OECD）等機構的公共衛生資料；企業資訊披露；藥局零售趨勢；以及有關非處方藥（成藥）標準、處方藥向非處方藥、電子商務記錄、標籤標準和已的藥物記錄趨勢。

結論

成藥市場正從傳統的處方箋產品產品類型演變為更廣泛的自我自我護理平台，這一演變受到監管、數位化管道、人工智慧驅動的營運以及消費者對便利醫療保健需求的共同影響。那些能夠將可靠的產品、清晰的標籤、完善的安全監測、符合監管規定的療效聲明以及卓越的銷售管道相結合的公司，將擁有最大的成長機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：非處方藥市場：依藥物類型分類

  • 感冒、咳嗽和過敏藥物
    • 抗組織胺藥
    • 止咳藥
    • 減充血劑
  • 皮膚科和護膚
    • 痤瘡治療藥物
    • 抗真菌乳膏
    • 皮膚保護劑
  • 消化器官系統健康
    • 制酸劑
    • 止瀉
    • 瀉藥
  • 眼耳護理
  • 止痛藥
  • 維生素和補充劑

第8章：非處方藥市場：以劑型分類

  • 膠囊
  • 液體和糖漿配方
  • 粉末
  • 噴
  • 栓劑
  • 片劑/藥丸
  • 外用乳霜、軟膏和凝膠

第9章 非處方藥市場：依分銷管道分類

  • 離線
    • 藥局/藥局
    • 超級市場和大賣場
  • 線上

第10章 非處方藥市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章 非處方藥市場：依最終使用者分類

  • 醫療保健專業人員
  • 個人消費者
  • 機構用戶

第12章 非處方藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 非處方藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非處方藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Inc.
  • Genomma group
  • GSK plc
  • Hisamitsu Pharmaceutical Co., Inc.
  • Johnson & Johnson Services, Inc.
  • LNK International, Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Pierre Fabre SA
  • PL Developments LLC
  • Procter & Gamble Manufacturing Company
  • Reckitt Benckiser LLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Taisho Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • The Mentholatum Company, Inc.
  • Tris Pharma, Inc.
  • Viatris Inc.
  • Worwag Pharma GmbH & Co. KG
  • Zentiva Group, as
Product Code: MRR-436297358D26

The Over The Counter Drugs Market is projected to grow by USD 103.96 billion at a CAGR of 9.03% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 56.75 billion
Estimated Year [2026] USD 61.50 billion
Forecast Year [2032] USD 103.96 billion
CAGR (%) 9.03%

The over-the-counter (OTC) drugs market is a critical pillar of global self-care, enabling consumers to manage common conditions such as pain, fever, allergies, cough and cold symptoms, digestive discomfort, dermatologic issues, and minor infections without a prescription when products are used as directed. Regulatory agencies including the U.S. Food and Drug Administration (FDA), European national competent authorities, and health ministries across Asia-Pacific continue to define OTC availability through safety, labeling, dosage, and pharmacovigilance standards.

Demand is being reinforced by aging populations, higher health awareness, rising out-of-pocket healthcare costs, and the expansion of pharmacy, mass retail, and digital commerce channels. The category is also benefiting from Rx-to-OTC switches, improved labeling, trusted nonprescription medicine brands, and consumer preference for convenient first-line treatment. For industry vendors, growth depends on balancing accessibility with evidence-based safety, transparent claims, supply reliability, and responsible digital engagement.

Transformative Shifts in the OTC Drugs Landscape

The OTC drugs landscape is shifting from product-led retailing to consumer-centered self-care ecosystems. Pharmacies remain trusted access points, but e-commerce, telehealth triage, mobile health applications, and omnichannel fulfillment are changing how consumers discover, compare, and purchase nonprescription medicines. This shift raises the importance of compliant digital content, clear dosage guidance, and search visibility for condition-based queries.

Regulatory modernization is another major force. In the United States, OTC monograph reform under the CARES Act created an administrative order process intended to update standards more efficiently. Globally, regulators are increasing scrutiny of labeling, adverse event reporting, ingredient safety, pediatric use, and claims substantiation. At the same time, inflationary pressure, active pharmaceutical ingredient supply constraints, and private-label competition are pushing manufacturers to strengthen procurement, portfolio segmentation, and brand trust.

Cumulative Impact of Artificial Intelligence on OTC Drugs

Artificial intelligence is becoming a cumulative advantage across the OTC drugs value chain. Manufacturers and retailers are applying AI to demand sensing, inventory planning, search optimization, consumer sentiment analysis, call-center support, and pharmacovigilance signal detection. These capabilities are especially valuable in seasonal categories such as cough, cold, flu, and allergy products, where demand can shift quickly by geography and public health conditions.

AI also supports safer consumer engagement when deployed with validated medical content and regulatory controls. Natural language processing can help monitor adverse event narratives, identify labeling comprehension gaps, and improve product information accessibility. However, AI in OTC drugs must remain governed by human oversight, data privacy safeguards, bias controls, and strict separation between educational support and unauthorized diagnosis or prescribing.

Key Regional Insights for OTC Drugs

Asia-Pacific is one of the most dynamic OTC drugs regions, supported by large populations, expanding middle-income groups, urban pharmacy modernization, and rapid adoption of online health retail. China, India, Japan, South Korea, Australia, and ASEAN markets show different regulatory models, but all are influenced by stronger consumer health awareness, aging demographics in several economies, and growing demand for accessible self-medication across analgesics, gastrointestinal remedies, allergy treatments, dermatology products, and cough, cold, and flu medicines.

North America remains a mature and innovation-driven OTC market, led by the United States and Canada, where established pharmacy chains, mass merchandisers, private labels, pharmacist engagement, and Rx-to-OTC switch pathways shape competition. Latin America is expanding through pharmacy-led access and affordability-focused purchasing, with Brazil and Mexico serving as major demand centers as consumers rely on nonprescription medicines for convenient symptom relief and first-line self-care.

Europe is characterized by high regulatory oversight, pharmacist involvement, and country-specific reimbursement, classification, advertising, and distribution rules that influence OTC product access. The Middle East is benefiting from healthcare infrastructure investment, high retail pharmacy penetration in GCC economies, and growing preference for branded consumer healthcare products. Africa presents long-term potential due to population growth and strong self-care needs, although development is shaped by affordability, distribution reach, counterfeit medicine risks, medicine quality controls, and uneven healthcare access.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are gaining relevance as rising urbanization, expanding retail pharmacy networks, and mobile-first consumers increase access to nonprescription medicines across major urban centers and emerging secondary cities. Regulatory harmonization remains gradual, so OTC market entry strategies must account for country-level labeling, registration, import requirements, local language standards, and health authority expectations.

The GCC is attractive for premium OTC brands because of high healthcare spending, modern retail formats, strong pharmacy infrastructure, and government investment in health system modernization. The European Union offers significant regulatory and commercial scale but requires careful navigation of national OTC classifications, pharmacovigilance obligations, language requirements, and advertising rules. BRICS economies combine large populations with expanding self-care adoption and growing domestic pharmaceutical capabilities, although pricing, local manufacturing policy, reimbursement norms, and regulatory complexity vary substantially.

G7 markets remain central for OTC innovation, consumer trust, clinical substantiation, quality standards, and Rx-to-OTC switch activity, supported by established regulatory systems and mature pharmacy channels. NATO countries overlap significantly with North American and European markets, where supply resilience, medicine security, active pharmaceutical ingredient availability, and trusted pharmaceutical distribution have become more strategic after recent global supply disruptions.

Key Country Insights for OTC Drugs

The United States leads global OTC innovation through a large retail base, FDA monograph standards, strong private-label competition, direct-to-consumer education, and continued interest in Rx-to-OTC switches. Canada emphasizes bilingual labeling, pharmacy trust, and safety-focused consumer access, while Mexico and Brazil offer scale in Latin America through high pharmacy utilization, urban retail expansion, and demand for affordable symptom relief.

In Europe, the United Kingdom, Germany, France, Italy, and Spain each maintain distinct OTC classification, advertising, reimbursement, and pharmacy practice norms. Germany and the United Kingdom are notable for established self-care cultures and broad consumer familiarity with pharmacy advice, while France, Italy, and Spain combine pharmacy-centered recommendations with growing digital engagement. Russia remains a sizable nonprescription medicine market, though geopolitical conditions, import constraints, and supply-chain conditions affect multinational participation and product availability.

China and India are pivotal OTC growth markets due to population scale, expanding e-commerce, rising health literacy, and growing self-medication awareness, but companies must manage regulatory localization, price sensitivity, distribution complexity, and local competition. Japan has a sophisticated switched-OTC framework and aging consumers seeking trusted remedies, while Australia maintains strong therapeutic goods regulation and a high level of pharmacy influence. South Korea combines high digital adoption with advanced retail health infrastructure and consumer interest in convenient, technology-enabled healthcare access.

Actionable Recommendations for OTC Drug Industry Leaders

Industry vendors should prioritize evidence-based portfolio expansion in high-demand OTC categories such as analgesics, allergy care, gastrointestinal relief, dermatology, and cough, cold, and flu products. Rx-to-OTC switch opportunities should be evaluated through safety history, consumer label comprehension, misuse risk, dosage clarity, post-market surveillance readiness, and pharmacist support requirements.

Companies should strengthen omnichannel execution by aligning retail availability, e-commerce search performance, compliant product education, and real-time demand planning. Investment in pharmacovigilance, serialization, anti-counterfeit controls, quality assurance, and supplier diversification is essential to protect consumers and defend brand equity. Companies should also develop responsible AI governance, ensuring that personalization and digital assistance improve access without compromising safety, privacy, or regulatory compliance.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. Inputs include regulatory guidance from agencies such as the FDA, European health authorities, and national ministries of health; public health data from organizations such as the World Health Organization and OECD; company disclosures; pharmacy retail trends; and documented developments in OTC monographs, Rx-to-OTC switches, e-commerce, labeling standards, and pharmacovigilance.

Insights are synthesized through qualitative market mapping across OTC product categories, channels, regions, regulatory environments, and consumer behavior drivers. The methodology emphasizes verifiable sources, cross-market comparison, and exclusion of unsupported estimates, sizing, share, or forecasting. Findings are designed to support strategic decision-making for manufacturers, distributors, retailers, investors, and healthcare stakeholders.

Conclusion

The OTC drugs market is advancing from a traditional nonprescription product category into a broader self-care platform shaped by regulation, digital access, AI-enabled operations, and consumer demand for convenient healthcare. Growth opportunities are strongest where organizations combine trusted products, clear labeling, robust safety monitoring, compliant claims, and channel excellence.

Future competitiveness will depend on responsible innovation, regional regulatory fluency, resilient supply chains, and credible consumer education. Organizations that treat OTC medicines as both healthcare products and consumer-facing solutions will be best positioned to support sustainable growth while protecting public health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Over The Counter Drugs Market, by Drug Type

  • 7.1. Cold, Cough, & Allergy Medications
    • 7.1.1. Antihistamines
    • 7.1.2. Cough Suppressants
    • 7.1.3. Decongestants
  • 7.2. Dermatology & Skin Care
    • 7.2.1. Acne Treatments
    • 7.2.2. Antifungal Creams
    • 7.2.3. Skin Protectants
  • 7.3. Digestive Health
    • 7.3.1. Antacids
    • 7.3.2. Anti-diarrheal
    • 7.3.3. Laxatives
  • 7.4. Eye & Ear Care
  • 7.5. Pain Relief Medications
  • 7.6. Vitamins & Supplements

8. Over The Counter Drugs Market, by Product Form

  • 8.1. Capsules
  • 8.2. Liquids/Syrups
  • 8.3. Powders
  • 8.4. Sprays
  • 8.5. Suppositories
  • 8.6. Tablets/Pills
  • 8.7. Topical Creams/Ointments/Gels

9. Over The Counter Drugs Market, by Distribution Channel

  • 9.1. Offline
    • 9.1.1. Pharmacies & Drug Stores
    • 9.1.2. Supermarkets & Hypermarkets
  • 9.2. Online

10. Over The Counter Drugs Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Over The Counter Drugs Market, by End-user

  • 11.1. Healthcare Professionals
  • 11.2. Individual Consumers
  • 11.3. Institutional Users

12. Over The Counter Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Over The Counter Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Over The Counter Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Amneal Pharmaceuticals LLC
  • 16.2. Aurobindo Pharma Limited
  • 16.3. Bayer AG
  • 16.4. Cipla Limited
  • 16.5. Dr. Reddy's Laboratories Inc.
  • 16.6. Genomma group
  • 16.7. GSK plc
  • 16.8. Hisamitsu Pharmaceutical Co., Inc.
  • 16.9. Johnson & Johnson Services, Inc.
  • 16.10. LNK International, Inc.
  • 16.11. Novartis AG
  • 16.12. Perrigo Company plc
  • 16.13. Pfizer Inc.
  • 16.14. Pierre Fabre S.A
  • 16.15. PL Developments LLC
  • 16.16. Procter & Gamble Manufacturing Company
  • 16.17. Reckitt Benckiser LLC
  • 16.18. Sanofi S.A.
  • 16.19. Sun Pharmaceutical Industries Limited
  • 16.20. Taisho Pharmaceutical Co., Ltd.
  • 16.21. Teva Pharmaceutical Industries Ltd
  • 16.22. The Mentholatum Company, Inc.
  • 16.23. Tris Pharma, Inc.
  • 16.24. Viatris Inc.
  • 16.25. Worwag Pharma GmbH & Co. KG
  • 16.26. Zentiva Group, a.s.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OVER THE COUNTER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OVER THE COUNTER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLD, COUGH, & ALLERGY MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLD, COUGH, & ALLERGY MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLD, COUGH, & ALLERGY MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIHISTAMINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIHISTAMINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIHISTAMINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COUGH SUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COUGH SUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COUGH SUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DECONGESTANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DECONGESTANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DECONGESTANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DERMATOLOGY & SKIN CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DERMATOLOGY & SKIN CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DERMATOLOGY & SKIN CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACNE TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACNE TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACNE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIFUNGAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIFUNGAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIFUNGAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SKIN PROTECTANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SKIN PROTECTANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SKIN PROTECTANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGESTIVE HEALTH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGESTIVE HEALTH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGESTIVE HEALTH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTACIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-DIARRHEAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-DIARRHEAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-DIARRHEAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LAXATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LAXATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LAXATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EYE & EAR CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EYE & EAR CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EYE & EAR CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PAIN RELIEF MEDICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAIN RELIEF MEDICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PAIN RELIEF MEDICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VITAMINS & SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VITAMINS & SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VITAMINS & SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIQUIDS/SYRUPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIQUIDS/SYRUPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIQUIDS/SYRUPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POWDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SPRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SPRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUPPOSITORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUPPOSITORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUPPOSITORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TABLETS/PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TABLETS/PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TABLETS/PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOPICAL CREAMS/OINTMENTS/GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TOPICAL CREAMS/OINTMENTS/GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TOPICAL CREAMS/OINTMENTS/GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACIES & DRUG STORES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACIES & DRUG STORES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACIES & DRUG STORES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUPERMARKETS & HYPERMARKETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUPERMARKETS & HYPERMARKETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUPERMARKETS & HYPERMARKETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HEALTHCARE PROFESSIONALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEALTHCARE PROFESSIONALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HEALTHCARE PROFESSIONALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INDIVIDUAL CONSUMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INDIVIDUAL CONSUMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INDIVIDUAL CONSUMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INSTITUTIONAL USERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSTITUTIONAL USERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INSTITUTIONAL USERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 180. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 181. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 210. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 211. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 220. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 221. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 286. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 296. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 306. ITALY OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 309. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 336. INDIA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 339. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 340. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 341. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 342. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 346. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 352. JAPAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)